{
    "Clinical Trial ID": "NCT00499083",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Vaccine",
        "  Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.",
        "  Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor.",
        "  Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV in a bi-weekly dose dense fashion",
        "  All patients had pre-treatment biopsy and second tumor biopsy after 4 cycles of paclitaxel to evaluate responses to the dendritic cell injections."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive breast cancer meeting the following criteria:",
        "  Primary tumor  3 cm by mammography, ultrasound, or palpation AND/OR palpable axillary lymph nodes > 1 cm",
        "  Survivin- and/or carcinoembryonic antigen-positive by IHC",
        "  Tumor must be localized by exam or ultrasound to allow tumor injection",
        "  No stage IV or metastatic disease",
        "  HER2/neu-negative tumor by IHC",
        "  If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required",
        "  Hormone receptor status known",
        "  PATIENT CHARACTERISTICS:",
        "  Female",
        "  Pre-, peri-, or postmenopausal",
        "  ECOG performance status 0-1",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for up to 6 months following completion of study therapy",
        "  ANC  1,500/mm\u00b3",
        "  Platelet count  100,000/mm\u00b3",
        "  Alkaline phosphatase  1.5 times upper limit of normal (ULN)",
        "  Total bilirubin  1.5 times ULN",
        "  AST and ALT  1.5 times ULN",
        "  Creatinine < 1.5 times ULN",
        "  No active serious infections",
        "  No prior malignancy except adequately treated basal cell or squamous cell skin cancer, noninvasive carcinoma, or other cancer from which the patient has been disease free for 5 years",
        "  No comorbidity or condition that would interfere with study assessments and procedures or preclude study participation",
        "  PRIOR CONCURRENT THERAPY:",
        "  No prior chemotherapy or radiotherapy"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients With Pathological Complete Response",
        "  Assessed by the institutional pathologist.",
        "  Grade 1: disappearance of all tumor on microscopic assessment in the breast and LNs",
        "  Grade 2: presence of in situ carcinoma only in the breast, no invasive tumor, and no tumor found in the LNs",
        "  Grade 3: presence of invasive carcinoma with stromal alteration, such as sclerosis or fibrosis",
        "  Grade 4: no or few modifications of the tumor appearance",
        "  Time frame: At definitive surgery.",
        "Results 1: ",
        "  Arm/Group Title: Vaccine",
        "  Arm/Group Description: Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.",
        "  Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor.",
        "  Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV in a bi-weekly dose dense fashion",
        "  All patients had pre-treatment biopsy and second tumor biopsy after 4 cycles of paclitaxel to evaluate responses to the dendritic cell injections.",
        "  Overall Number of Participants Analyzed: 14",
        "  Measure Type: Number",
        "  Unit of Measure: participants  2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/3 (33.33%)",
        "  Febrile neutropenia 1/3 (33.33%)"
    ]
}